Drugs /

sarilumab

Back to Drugs List

Overview

NCI Definition [1]:
A recombinant, human immunoglobulin (IgG) monoclonal antibody targeting the interleukin 6 receptor (IL-6R), with potential anti-inflammatory activity. Upon intravenous administration of sarilumab, this agent targets and binds to both soluble IL-6 receptor (sIL-6R) and membrane-bound IL-6 receptor (mIL-6R). This inhibits the binding of the pro-inflammatory cytokine IL-6 to the IL-6 receptor (IL-6R), which results in the blockade of the IL-6/IL-6R-mediated signal transduction pathway. This may inhibit IL-6/IL-6R-mediated inflammation.

Clinical Trials

View Clinical Trials for sarilumab

Sarilumab has been investigated in 2 clinical trials, of which 2 are open and 0 are closed. Of the trials investigating sarilumab, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open).

ER Negative, ER No Expression, and HER2 Deficient Expression are the most frequent biomarker inclusion criteria for sarilumab clinical trials.

Breast carcinoma and indolent systemic mastocytosis are the most common diseases being investigated in sarilumab clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Sarilumab
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating sarilumab and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
regn88, sar153191, kevzara, immunoglobulin g1, anti-human interleukin 6 receptor alpha) (human regn88 heavy chain), disulfide with human regn88 light chain, dimer, sarilumab, sarilumab
Drug Target(s) [2]:
IL6R
NCIT ID [1]:
C152302

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.